Stoke Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $13,817 | $158,569 | $22,614 | $4,894 |
Gross Profit | 13,817 | 158,569 | 22,614 | 4,894 |
EBITDA | -26,854 | 111,717 | -13,127 | -29,463 |
EBIT | -27,300 | 111,240 | -13,653 | -30,003 |
Net Income | -23,483 | 112,879 | -10,482 | -26,430 |
Net Change In Cash | 13,817 | 158,569 | 22,614 | 4,894 |
Free Cash Flow | -25,576 | 131,675 | -23,235 | -21,718 |
Cash | 101,472 | 274,817 | 127,983 | 150,016 |
Basic Shares | 58,353 | 59,398 | 57,029 | 56,341 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $36,555 | $8,780 | $12,405 | $3,000 |
Gross Profit | 36,555 | 8,780 | 12,405 | -2,230 |
EBITDA | -99,195 | -112,304 | -102,810 | -85,091 |
EBIT | -101,372 | -114,773 | -104,356 | -86,065 |
Net Income | -88,981 | -104,699 | -93,110 | -84,711 |
Net Change In Cash | 36,555 | 8,780 | 12,405 | 3,000 |
Cost of Revenue | -31,339 | -142,049 | ||
Free Cash Flow | -87,054 | -82,683 | -35,828 | -68,107 |
Cash | 127,983 | 191,442 | 113,556 | 144,895 |
Basic Shares | 54,008 | 43,994 | 38,897 | 36,739 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.40 |
2025-03-31 | $1.90 |
2024-12-31 | -$0.18 |
